DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Goldman Sachs Initiates Coverage On Arrowhead Pharmaceuticals with Neutral Rating, Announces $45 Price Target

Goldman Sachs analyst Salveen Richter initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Neutral rating and a $45 price target.

Benzinga · 03/17/2020 09:57

Goldman Sachs analyst Salveen Richter initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Neutral rating and a $45 price target.